Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years

Hely, Mariese A., Morris, John G.L., Reid, Wayne G.J., Trafficante, Robert·2005·Movement Disorders

DOI 10.1002/mds.20324

Cited by (1,000)

Items 201–300 of 1,000

NLX-112, a novel 5-HT 1A receptor agonist for the treatment of l -DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat
Hanna Iderberg, Andrew C. McCreary, Mark A. Varney, Mark S. Kleven, Wouter Koek, Laurent Bardin, Ronan Depoortère, Maria Angela Cenci, Adrian Newman‐Tancredi · 2015 · Experimental Neurology
Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD
Daan C. Velseboer, Mark Broeders, Bart Post, Nan van Geloven, Johannes Dirk Speelman, Ben A. Schmand, Rob J. de Haan, Rob M. A. de Bie, on behalf of the CARPA Study Group · 2013 · Neurology
Microglial Phagocytosis of Neurons: Diminishing Neuronal Loss in Traumatic, Infectious, Inflammatory, and Autoimmune CNS Disorders
Samuel F. Yanuck · 2019 · Frontiers in Psychiatry
The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson’s Disease
Lingyu Zhang, Liping Zhang, Yanwei Li, Lin Li, Josefine Ulrikke Melchiorsen, METTE MARIE ROSENKILDE, Christian Hölscher · 2020 · Journal of Parkinson s Disease
Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson's Disease
Barbara S. Connolly, Susan Helen Fox · 2013 · Neurotherapeutics
Alpha-synuclein transgenic mice display age-related slowing of gastrointestinal motility associated with transgene expression in the vagal system
Ali Reza Noorian, Jennifer Rha, Dana M. Annerino, Douglas Bernhard, Georgia M. Taylor, James G. Greene · 2012 · Neurobiology of Disease
Tai Chi Exercise to Improve Non-Motor Symptoms of Parkinson’s Disease
Joe R Nocera Shinichi Amano, Srikanth VVallabhajosula Chris J Hass · 2013 · Journal of Yoga & Physical Therapy
Drug Delivery Systems for Imaging and Therapy of Parkinson';s Disease
Mine Silindir‐Gunay, A. Yekta Özer, Sylvie Chalon · 2015 · Current Neuropharmacology
Dopaminergic transplantation for parkinson's disease: Current status and future prospects
C. Warren Olanow, Jeffrey H. Kordower, Anthony Edward Lang, Jose Angel Obeso · 2009 · Annals of Neurology
Do patients with late-stage Parkinson's disease still respond to levodopa?
Margherita Fabbri, Miguel M Coelho, Daisy Abreu, Leonor Correia Guedes, Mário Miguel Rosa, Nilza Costa, Angelo Antonini, Joaquim José Ferreira · 2016 · Parkinsonism & Related Disorders
Diffusion alterations associated with Parkinson's disease symptomatology: A review of the literature
Julie M. Hall, Kaylena A. Ehgoetz Martens, Courtney Campbell Walton, Claire O’Callaghan, Peter E. Keller, Simon J.G. Lewis, Ahmed A. Moustafa · 2016 · Parkinsonism & Related Disorders
What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson’s Disease: A Post Hoc Analysis
Dilan S. Athauda, Kate Maclagan, Natalia Budnik, Luca Zampedri, Steve Hibbert, Simon S. Skene, Kashfia Chowdhury, Icíar Avilés-Olmos, Patricia Dowsey Limousin, Thomas Foltynie · 2018 · Journal of Parkinson s Disease
Neuropsychiatric Issues in Parkinson’s Disease
Jeffrey W. Cooney, Mark A. Stacy · 2016 · Current Neurology and Neuroscience Reports
Multidisciplinary care for people with Parkinson’s disease: the new kids on the block!
Danique L. M. Radder, Nienke M. de Vries, Niels Peter Riksen, Sarah J. Diamond, D. R. Gross, Daniel R. Gold, John P.F.A. Heesakkers, Emily J. Henderson, Adrianus L.A.J. Hommel, Herma H. Lennaerts et al. · 2018 · Expert Review of Neurotherapeutics
Large-Scale Wearable Sensor Deployment in Parkinson’s Patients: The Parkinson@Home Study Protocol
Silva de Lima, Ana Lígia, Hahn, Tim, de Vries, Nienke M, Cohen, Eli, Bataille, Lauren, Little, Max A, Baldus, Heribert, Bloem, Bastiaan R, Faber, Marjan J · 2016 · JMIR Research Protocols
Impact of pramipexole on the onset of levodopa‐related dyskinesias
Radu Constantinescu, Megan Romer, Michael McDermott, Cornelia Kamp, Karl D. Kieburtz · 2007 · Movement Disorders
Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease
Lindy D. Wood, Joshua J. Neumiller, Stephen M. Setter, Erin K. Dobbins · 2010 · The American Journal of Geriatric Pharmacotherapy
Measuring symptom load in Idiopathic Parkinson's disease
Malcolm Lee, Wendy M. Prentice, A.J. Hildreth, Richard William Walker · 2007 · Parkinsonism & Related Disorders
Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and Treatments
Elmyra V. Encarnacion, Robert A. Hauser · 2008 · European Neurology
Parkinson’s Disease and Cognitive Impairment
Yang Yang, Beisha Tang, Jifeng Guo · 2016 · Parkinson s Disease
A Review of the Clinical Evidence for Complementary and Alternative Therapies in Parkinson’s Disease
Danny Bega, Paulina González-Latapí, Cindy Zadikoff, Tanya Simuni · 2014 · Current Treatment Options in Neurology
Missing Dosages and Neuroleptic Usage May Prolong Length of Stay in Hospitalized Parkinson's Disease Patients
Daniel Martínez-Ramírez, Juan C. Giugni, Christopher Scott Little, John P. Chapman, Bilal Ahmed, Erin Hastings, Aparna Wagle Shukla, Christopher W. Hess, Michael S. Okun · 2015 · PLoS ONE
Activity of serotonin 5-HT1A receptor ‘biased agonists’ in rat models of Parkinson's disease and l-DOPA-induced dyskinesia
Hanna Iderberg, Andrew C. McCreary, Mark A. Varney, Maria Angela Cenci, Adrian Newman‐Tancredi · 2015 · Neuropharmacology
Parkinson Disease: The Relationship Between Non-motor Symptoms and Motor Phenotype
Fang Ba, Mona Talib Obaid, Marguerite Wieler, Richard M. Camicioli, W. R. Wayne Martin · 2015 · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Impaired Quality of Life and Need for Palliative Care in a German Cohort of Advanced Parkinson’s Disease Patients
Martin Klietz, A. Tulke, Lars Hendrik Müschen, Lejla Paracka, Christoph Schrader, Dirk W. Dressler, Florian Wegner · 2018 · Frontiers in Neurology
GLP-1 receptor agonists for Parkinson's disease
Caroline A. Mulvaney, Gonçalo Silva Duarte, Joel D. Handley, David JW Evans, Suresh Menon, Richard K H Wyse, Hedley C A Emsley · 2020 · Cochrane Database of Systematic Reviews
Does levodopa accelerate the pathologic process in Parkinson disease brain?
Laura Parkkinen, Sean S. O’Sullivan, Mikko Kuoppamäki, C. Collins, Constantinos Kallis, Janice L. Holton, D. R. Williams, Tamás Révész, Andrew John Lees · 2011 · Neurology
Exergaming as a Viable Therapeutic Tool to Improve Static and Dynamic Balance among Older Adults and People with Idiopathic Parkinson’s Disease: A Systematic Review and Meta-Analysis
Dale M. Harris, Timo Rantalainen, Makii Muthalib, Liam G Johnson, Wei‐Peng Teo · 2015 · Frontiers in Aging Neuroscience
The estimated life expectancy in a community cohort of Parkinson's disease patients with and without dementia, compared with the UK population
Peter Hobson, Jolyon Meara, L. Ishihara-Paul · 2010 · Journal of Neurology Neurosurgery & Psychiatry
Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test
Margherita Fabbri, Miguel M Coelho, Leonor Correia Guedes, Inês Chendo, Ana Catarina Sousa, Mário Miguel Rosa, Daisy Abreu, Nilza Costa, Catarina Godinho, Angelo Antonini et al. · 2017 · Parkinsonism & Related Disorders
The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease
James B. Koprich, Susan Helen Fox, Tom H. Johnston, Allan Goodman, Bertrand Le Bourdonnec, Roland E. Dolle, Robert N. DeHaven, Diane L. DeHaven‐Hudkins, Patrick Little, Jonathan M. Brotchie · 2011 · Movement Disorders
Causes and Consequences of Degeneration of the Dorsal Motor Nucleus of the Vagus Nerve in Parkinson's Disease
James G. Greene · 2014 · Antioxidants and Redox Signaling
Clinical validation of movement disorder society–recommended diagnostic criteria for Parkinson's disease with dementia
Brandon R. Barton, David Grabli, Bryan A. Bernard, Virginie Czernecki, Jennifer G. Goldman, Glenn T. Stebbins, Bruno Dubois, Christopher G. Goetz · 2011 · Movement Disorders
Visual hallucinations in the differential diagnosis of parkinsonism: Table 1
Kelly Bertram, David R. Williams · 2012 · Journal of Neurology Neurosurgery & Psychiatry
Palliative Care for Parkinson’s Disease: Has the Time Come?
Janis M. Miyasaki, Benzi M. Kluger · 2015 · Current Neurology and Neuroscience Reports
Cognitive Rehabilitation for Executive Dysfunction in Parkinson's Disease: Application and Current Directions
Jessica Calleo, Cristina Burrows, Harvey S. Levin, Laura Marsh, Eugene C. Lai, Michele K. York · 2011 · Parkinson s Disease
Curcumin restores rotenone induced depressive-like symptoms in animal model of neurotoxicity: assessment by social interaction test and sucrose preference test
Syeda Madiha, Saida Haider · 2018 · Metabolic Brain Disease
Hippocampal CA1 subfield predicts episodic memory impairment in Parkinson's disease
Christian La, Patricia Linortner, Jeffrey D. Bernstein, Matthew A. I. Ua Cruadhlaoich, Michelle C. Fenesy, Gayle Karen Deutsch, Brian K. Rutt, Lü Tian, Anthony D. Wagner, Michael Zeineh et al. · 2019 · NeuroImage Clinical
Parkinsonism and Related Disorders
Elizabeth Slow, Anthony Edward Lang · 2019 · DeckerMed Transitional Year Weekly Curriculum™
Depression and anxiety among patients with Parkinson’s disease: frequency, risk factors, and impact on quality of life
Khedr, Eman M., Abdelrahman, Ahmed A., Elserogy, Yasser, Zaki, Ahmed Fathi, Gamea, Ayman · 2020 · The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
GBA -Associated Parkinson’s Disease: Progression in a Deep Brain Stimulation Cohort
Vanessa Lythe, Dilan S. Athauda, Jennifer A. Foley, Niccolò Emanuele Mencacci, Marjan Jahanshahi, Lisa Cipolotti, Jonathan A. Hyam, Ludvic U. Zrinzo, Marwan I. Hariz, John Hardy et al. · 2017 · Journal of Parkinson s Disease
Pedunculopontine Nucleus Stimulation: Where are We Now and What Needs to be Done to Move the Field Forward?
Hokuto Morita, Chris J. Hass, Elena Moro, Atchar Sudhyadhom, Rajeev Kumar, Michael S. Okun · 2014 · Frontiers in Neurology
Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease
Poewe, Werner, Mahlknecht, Philipp · 2020 · Neurologic Clinics
Lack of association of APOE and tau polymorphisms with dementia in Parkinson’s disease
Mario Ezquerra, Jaume Campdelacreu, Carles Gaig, Yaroslau Compta, Esteban Muñoz, Marı́a José Martı́, Francesc Valldeoriola, EDUARDO S. TOLOSA · 2008 · Neuroscience Letters
What are the issues facing Parkinson's disease patients at ten years of disease and beyond?: Data from the NPF-QII study
Anhar Hassan, Samuel Shangwu Wu, Peter N. Schmidt, Irene A. Malaty, Yun Feng Dai, Janis M. Miyasaki, Michael S. Okun · 2012 · Parkinsonism & Related Disorders
Future Treatments for Parkinson's Disease: Surfing the PD Pipeline
Robert A. Hauser · 2011 · International Journal of Neuroscience
Pituitary adenylate cyclase-activating polypeptide (PACAP) has neuroprotective function in dopamine-based neurodegeneration developed in two parkinsonian models
Gábor Maász, Zita Zrínyi, Dóra Reglődi, D. Petrovics, Adam Rivnyak, T. Kiss, Adél Jüngling, Andrea Tamás, Zsolt Pirger · 2016 · Disease Models & Mechanisms
Non-motor Symptoms of Parkinson's Disease
К. Ray Chaudhuri, Eduardo Tolosa, Anthony H.V. Schapira, Werner H Poewe · 2014 · Oxford University Press eBooks
Dysphagia predicts poor outcome in late-stage Parkinson's disease
Margherita Fabbri, Miguel M Coelho, Daisy Abreu, Leonor Correia Guedes, Mário Miguel Rosa, Catarina Godinho, Rita Cardoso, Isabel Guimarães, Angelo Antonini, Maurizio Zibetti et al. · 2019 · Parkinsonism & Related Disorders
Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease
Maria Angela Cenci, Katrine Skovgård, Per Odin · 2022 · Neuropharmacology
Levodopa/dopamine replacement strategies in Parkinson's disease-Future directions
C. Warren Olanow · 2008 · Movement Disorders
Voxel-based meta-analysis of gray matter volume reductions associated with cognitive impairment in Parkinson’s disease
Yaqian Xu, Jing Yang, Xinyu Hu, Huifang Shang · 2016 · Journal of Neurology
Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease
J. Eric Ahlskog · 2009 · Parkinsonism & Related Disorders
Emerging therapies for gait disability and balance impairment: Promises and pitfalls
Maetzler, Walter, Nieuwhof, Freek, Hasmann, Sandra E., Bloem, Bastiaan R. · 2013 · Movement Disorders
Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed
Nataliya Titova, Pablo Martínez‐Martín, Е А Катунина, К. Ray Chaudhuri · 2017 · Journal of Neural Transmission
Dementia in long-term Parkinson’s disease patients: a multicentre retrospective study
Jennifer Y. Y. Szeto, Courtney Campbell Walton, Alexandra Rizos, Pablo Martínez‐Martín, Glenda Margaret Halliday, Sharon Linda Naismith, К. Ray Chaudhuri, Simon J.G. Lewis · 2020 · npj Parkinson s Disease
Longitudinal study of the motor response to levodopa in Parkinson's disease
Benjamin G. Clissold, Craig D. McColl, Katrina A. Reardon, Mark Shiff, Peter A. Kempster · 2006 · Movement Disorders
l-Dopa-Induced Dyskinesia—Clinical Presentation, Genetics, and Treatment
Prashanth Lingappa Kukkle, Susan Helen Fox, Wassilios G. Meissner · 2011 · International review of neurobiology
Cognitive dysfunction and depression in Parkinson’s disease: what can be learned from rodent models?
Hanna S. Lindgren, Stephen B. Dunnett · 2012 · European Journal of Neuroscience
Current strategies in the treatment of Parkinson’s disease and a personalized approach to management
Nancy L. Diaz, Cheryl Waters · 2009 · Expert Review of Neurotherapeutics
Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS
Jennifer G. Goldman, Glenn T. Stebbins, Vania Leung, Barbara C. Tilley, Christopher G. Goetz · 2014 · Parkinsonism & Related Disorders
The Integrative Care of Parkinson's Disease: A Systematic Review
Lindsay Penny Prizer, Nina Browner · 2012 · Journal of Parkinson s Disease
Advanced Parkinson's disease: Clinical characteristics and treatment (part 1)
Jaime Kulisevsky, M. R. Luquín, José Matías Arbelo, Juan Andrés Burguera, F. Carrillo, A. Castro, J. Chacón, Pedro Ruiz, E. Lezcano, Pablo Mir et al. · 2013 · Neurología (English Edition)
The impact of histone post-translational modifications in neurodegenerative diseases
Samantha N. Cobos, Seth A. Bennett, Mariana P. Torrente · 2018 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Enfermedad de Parkinson avanzada. Características clínicas y tratamiento (parte I)
Jaime Kulisevsky, M. R. Luquín, José Matías Arbelo, Juan Andrés Burguera, F. Carrillo, A. Castro, J. Chacón, Pedro Ruiz, E. Lezcano, Pablo Mir et al. · 2013 · Neurología
Clinical correlates of pathology in the claustrum in Parkinson's disease and dementia with Lewy bodies
Michail E. Kalaitzakis, R. K. B. Pearce, Steve Gentleman · 2009 · Neuroscience Letters
Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease
Eva Schaeffer, Andrea Pilotto, Daniela Berg · 2014 · CNS Drugs
Natural history of falls in a population-based cohort of patients with Parkinson's disease: An 8-year prospective study
Ylva Hivand Hiorth, Jan Petter Larsen, Kirsten Lode, Kenn Freddy Pedersen · 2014 · Parkinsonism & Related Disorders
Hallucinations and psychosis in Parkinson's disease
Jose M. Rabey · 2009 · Parkinsonism & Related Disorders
Long-Term Outcomes of Genetic Parkinson’s Disease
Jan Olav Aasly · 2020 · Journal of Movement Disorders
Development of Small Molecules Targeting α-Synuclein Aggregation: A Promising Strategy to Treat Parkinson’s Disease
Samuel Peña‐Díaz, Javier García‐Pardo, Salvador Ventura · 2023 · Pharmaceutics
Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia
Yaroslau Compta, Naroa Ibarretxe‐Bilbao, Joana B. Pereira, Carme Junqué, Núria Bargalló, EDUARDO S. TOLOSA, Francesc Valldeoriola, Esteban Muñoz, Ana Cámara, Maríateresa Buongiorno et al. · 2012 · Parkinsonism & Related Disorders
Prognostic Factors of Subthalamic Stimulation in Parkinson’s Disease: A Comparative Study between Short- and Long-Term Effects
Sheng‐Tzung Tsai, Sheng-Huang Lin, Yu‐Cheng Chou, Yan-Hong Pan, Hsiang-Yi Hung, Chi-Wei Li, Shinn‐Zong Lin, Shin-Yuan Chen · 2009 · Stereotactic and Functional Neurosurgery
Dementia and subthalamic deep brain stimulation in Parkinson disease
Francesco Bove, Valérie Fraix, Francesco Cavallieri, Emmanuelle Schmitt, Eugénie Lhommée, Amélie Bichon, Sara Meoni, Pierre Pélissier, Andrea Kistner, Eric Chevrier et al. · 2020 · Neurology
Unmet Needs of Patients with Parkinson's Disease: Interview Survey of Patients and Caregivers
Taku Hatano, S-I Kubo, Yasushi Shimo, Kenya Nishioka, Nobutaka Hattori · 2009 · Journal of International Medical Research
Circumstances of falls and fall-related injuries among patients with Parkinson's disease in an outpatient setting
Tatjana M. Gazibara, Tatjana D. Pekmezovic, Darija Kisić-Tepavčević, Aleksandra Tomić, Iva Stanković, Vladimir Kostić, Marina V. Svetel · 2014 · Geriatric Nursing
Role of homocysteine in the treatment of Parkinson's disease
Thomas H. Müller · 2008 · Expert Review of Neurotherapeutics
5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA
Philippe Huot, Tom H. Johnston, Lieke Winkelmolen, Susan Helen Fox, Jonathan M. Brotchie · 2010 · Neurobiology of Aging
Medical therapy and subthalamic deep brain stimulation in advanced Parkinson's disease: a different long-term outcome?
Aristide Merola, Laura Rizzi, Maurizio Zibetti, Carlo Alberto Artusi, Elisa Montanaro, Serena Angrisano, Michele Lanotte, Mario Giorgio Rizzone, Leonardo Lopiano · 2013 · Journal of Neurology Neurosurgery & Psychiatry
Current concepts in the management of Parkinson disease
Michael William Hayes, Victor S.C. Fung, Thomas Edmund Kimber, John D. O’Sullivan · 2010 · The Medical Journal of Australia
Mood Effects After Deep Brain Stimulation for Parkinson's Disease: An Update
Ettore A. Accolla, Claudio Pollo · 2019 · Frontiers in Neurology
Systematic review for the prevention and management of falls and fear of falling in patients with Parkinson's disease
Wen‐Yi Liu, Tao‐Hsin Tung, Chencheng Zhang, Leiyu Shi · 2022 · Brain and Behavior
Levodopa/carbidopa/entacapone in Parkinson’s disease
Lauren Seeberger, Robert A. Hauser · 2009 · Expert Review of Neurotherapeutics
Human gene therapy approaches for the treatment of Parkinson's disease: An overview of current and completed clinical trials
Frederick L. Hitti, Andrew I. Yang, Pedro Gonzalez‐Alegre, Gordon H. Baltuch · 2019 · Parkinsonism & Related Disorders
Parkinson's disease: 10 years of progress, 1997–2007
Stanley Fahn · 2010 · Movement Disorders
When does Parkinson's disease begin? From prodromal disease to motor signs
Wassilios G. Meissner · 2012 · Revue Neurologique
Levodopa-induced dyskinesia: a historical review of Parkinson’s disease, dopamine, and modern advancements in research and treatment
Carissa A. Hansen, Douglas R. Miller, Stephanie Annarumma, Carley T. Rusch, Adolfo Ramirez‐Zamora, Habibeh Khoshbouei · 2022 · Journal of Neurology
Augmented visual feedback-aided interventions for motor rehabilitation in Parkinson’s disease: a systematic review
Elaine Kearney, Sanjana Shellikeri, Rosemary Martino, Yana Yunusova · 2018 · Disability and Rehabilitation
Early (Uncomplicated) Parkinson's Disease
Wolfgang Hermann Oertel, Alfredo Berardelli, Bastiaan R. Bloem, Ubaldo Bonuccelli, David John Burn, Günther Deuschl, Espen Dietrichs, Giovanni Fabbrini, Joaquim José Ferreira, A. Friedman et al. · 2010
18F-Fluorodeoxyglucose PET in the Evaluation of Parkinson Disease
Kathleen L. Poston, David Eidelberg · 2010 · PET Clinics
Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson's disease
Tom H. Johnston, Anne van der Meij, Jonathan M. Brotchie, Susan Helen Fox · 2010 · Movement Disorders
Validation of the Korean Version of the Scale for Outcomes in Parkinson’s Disease-Autonomic
Ji‐Young Kim, In‐Uk Song, Seong‐Beom Koh, Tae‐Beom Ahn, Sang Jin Kim, Sang‐Myung Cheon, Jin Whan Cho, Yun Joong Kim, Hyeo-Il Ma, Mee-Young Park et al. · 2017 · Journal of Movement Disorders
Distinct alterations in Parkinson's medication-state and disease-state connectivity
Bernard Ng, Gael P. Varoquaux, Jean‐Baptiste Poline, Bertrand Thirion, Michael D. Greicius, Kathleen L. Poston · 2017 · NeuroImage Clinical
Striatal changes in Parkinson disease: An investigation of morphology, functional connectivity and their relationship to clinical symptoms
Conor Owens‐Walton, David Jakabek, Xiaozhen Li, Fiona Wilkes, Mark Walterfang, Dennis Velakoulis, Danielle van Westen, Jeffrey CL Looi, Oskar Hansson · 2018 · Psychiatry Research Neuroimaging
The Prevalence and Determinants of Neuropsychiatric Symptoms in Late‐Stage Parkinsonism
A. Hommel, M. Meinders, S. Lorenzl, R. Dodel, M. Coelho, J. Ferreira, B. Laurens, U. Spampinato, W. Meissner, K. Rosqvist et al. · 2020 · Movement Disorders Clinical Practice
Parkinson Disease in Long Term Care Facilities: A Review of the Literature
Nico J. Weerkamp, Gerrit Tissingh, Petra J. E. Poels, Sytse Ulbe Zuidema, Marten Munneke, Raymond T.C.M. Koopmans, Bastiaan R. Bloem · 2013 · Journal of the American Medical Directors Association
Serotonin hyperinnervation of the striatum with high synaptic incidence in parkinsonian monkeys
Dave Gagnon, Laurent Grégoire, Thérèse Di Paolo, Martin Parent · 2015 · Brain Structure and Function
Dementia and severity of parkinsonism determines the handicap of patients in late‐stage Parkinson's disease: the Barcelona−Lisbon cohort
Miguel M Coelho, M. J. Martí, Cristina Sampaio, Joaquim José Ferreira, Francesc Valldeoriola, Mário Miguel Rosa, EDUARDO S. TOLOSA · 2014 · European Journal of Neurology
The Epidemiology of Parkinson's Disease
Shin-Yuan Chen, Sheng‐Tzung Tsai · 2010 · Tzu Chi Medical Journal
Perspectives on Parkinson Disease Care in Dutch Nursing Homes
Anouke van Rumund, Nico J. Weerkamp, Gerrit Tissingh, Sytse Ulbe Zuidema, Raymond T.C.M. Koopmans, Marten Munneke, Petra J. E. Poels, Bastiaan R. Bloem · 2014 · Journal of the American Medical Directors Association